Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial

Pathogen reduction (PR) technologies for blood components have been established to reduce the residual risk of known and emerging infectious agents. THERAFLEX UV-Platelets, a novel ultraviolet C (UVC) light-based PR technology for platelet concentrates, works without photoactive substances. This randomized, controlled, double-blind, multicenter, non-inferiority trial was designed to compare the efficacy and safety of UVC-treated platelets to that of untreated platelets in thrombocytopenic patients with hematologic-oncologic diseases. The primary objective was to determine non-inferiority of UVC-treated platelets, assessed by the 1-hour corrected count increment (CCI) in up to eight per-protocol platelet transfusion episodes. Analysis of the 171 eligible patients showed that the defined non-inferiority margin of 30% of UVC-treated platelets was narrowly missed as the mean differences in 1-hour CCI between standard platelets versus UVC-treated platelets for intention-to-treat and per-protocol analyses were 18.2% (95% Confidence Interval [CI]: 6.4-30.1) and 18.7% (95% CI: 6.3-31.1), respectively. In comparison to the control, the UVC group had a 19.2% lower mean 24-hour CCI and was treated with an about 25% higher number of platelet units, but the average number of days to the next platelet transfusion did not differ significantly between both treatment groups. The frequency of low-grade adverse events was slightly higher in the UVC group and the frequencies of refractoriness to platelet transfusion, platelet alloimmunization, severe bleeding events, and red blood cell transfusions were comparable between groups. Our study suggests that transfusion of pathogen-reduced platelets produced with the UVC technology is safe but non-inferiority was not demonstrated. (clinicaltrials gov. Identifier: DRKS00011156).

[1]  N. Heddle,et al.  Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion , 2020, Transfusion.

[2]  P. Rebulla,et al.  A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets , 2020, Transfusion.

[3]  Suzanne R. Thibodeaux,et al.  Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivation. , 2019, Seminars in hematology.

[4]  W. Handke,et al.  Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system , 2018, Transfusion.

[5]  A. ten Brinke,et al.  The role of pathogen‐reduced platelet transfusions on HLA alloimmunization in hemato‐oncological patients , 2018, Transfusion.

[6]  T. Hervig,et al.  Hemostatic efficacy of pathogen-inactivated-versus untreated-platelets : a randomized controlled trial , 2018 .

[7]  E. Deconinck,et al.  Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study , 2018, Transfusion.

[8]  W. Handke,et al.  Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively , 2018, Transfusion.

[9]  A. Buser,et al.  Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland , 2018, Transfusion Medicine and Hemotherapy.

[10]  E. Deconinck,et al.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial , 2018, JAMA oncology.

[11]  P. Provost,et al.  Pathogen reduction technologies: The pros and cons for platelet transfusion , 2018, Platelets.

[12]  Y. Latchman,et al.  Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. , 2017, Blood.

[13]  M. Graf,et al.  Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologies , 2017, Transfusion.

[14]  M. Muench,et al.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood , 2017, Transfusion.

[15]  R. Benjamin,et al.  Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre , 2017, Vox sanguinis.

[16]  P. Bolton-Maggs.  SHOT conference report 2016: serious hazards of transfusion – human factors continue to cause most transfusion‐related incidents , 2016, Transfusion medicine.

[17]  Richtlinie Hämotherapie.  Berlin, 15. Juli 2016 – Stellungnahme zum Entwurf der „Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie)“ , 2016, Geburtshilfe und Frauenheilkunde.

[18]  B. Custer,et al.  Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications , 2016, Transfusion.

[19]  J. Gris,et al.  Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data , 2016, Transfusion.

[20]  A. Seltsam,et al.  Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light , 2016, Transfusion.

[21]  R. Benjamin,et al.  The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen‐ultraviolet A pathogen reduction treatment model , 2016, Transfusion.

[22]  D. de Korte,et al.  Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? , 2015, Transfusion.

[23]  D. Deeren,et al.  Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions , 2015, Transfusion.

[24]  T. Kohlmann,et al.  Tolerance of platelet concentrates treated with UVC‐light only for pathogen reduction – a phase I clinical trial , 2015, Vox sanguinis.

[25]  A. Seltsam,et al.  Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products , 2015, Transfusion.

[26]  J. M. Rubio,et al.  The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets , 2014, Transfusion.

[27]  S. Stramer.  Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections , 2014, ISBT science series.

[28]  Nancy M. Heddle,et al.  Clinical trials evaluating pathogen‐reduced platelet products: methodologic issues and recommendations , 2013, Transfusion.

[29]  A. Gratwohl,et al.  Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components , 2013, Transfusion.

[30]  A. Seltsam,et al.  Update on the use of pathogen‐reduced human plasma and platelet concentrates , 2013, British journal of haematology.

[31]  E. Wood,et al.  A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.

[32]  A. Seltsam,et al.  Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets , 2013, Transfusion.

[33]  T. Pietschmann,et al.  Two pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood products , 2013, Transfusion.

[34]  M. Trivella,et al.  Pathogen-reduced platelets for the prevention of bleeding. , 2013, The Cochrane database of systematic reviews.

[35]  A. Seltsam,et al.  Evaluation of the tolerability and immunogenicity of ultraviolet C‐irradiated autologous platelets in a dog model , 2012, Transfusion.

[36]  A. Ho,et al.  Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.

[37]  C. Prowse,et al.  A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion , 2011, British journal of haematology.

[38]  A. Seltsam,et al.  UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma , 2011, Transfusion Medicine and Hemotherapy.

[39]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[40]  W. van Putten,et al.  Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction , 2010, British journal of haematology.

[41]  Jeffrey McCullough,et al.  Dose of prophylactic platelet transfusions and prevention of hemorrhage. , 2010, The New England journal of medicine.

[42]  T. Müller,et al.  Sterilization of platelet concentrates at production scale by irradiation with short‐wave ultraviolet light , 2009, Transfusion.

[43]  L. Corash,et al.  Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use , 2009, Transfusion.

[44]  R. Brand,et al.  A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. , 2006, Blood.

[45]  J. Cazenave,et al.  Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set , 2005, Transfusion.

[46]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[47]  J. Fridey,et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. , 2004, Blood.

[48]  P. Ljungman,et al.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. , 2003, Blood.

[49]  A. Shanwell,et al.  Storage of Platelets in Additive Solutions: Effects of Phosphate , 2000, Vox Sanguinis.

[50]  M. Darrach.  Round-Table Discussion , 2012, Drugs.

[51]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[52]  W. J. Hadden,et al.  A Comparison of , 1971 .